TRPC6 Inhibition Attenuates Renal Tubulointerstitial Fibrosis via the Reactive Oxygen Species/TXNIP/NLRP3 Signaling Pathway
Kidney and Blood Pressure Research · 24.04.2026 · 51 (1) · 452-467
DOI: 10.1159/000552129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, online erschienen am 24.04.2026. Verfasst von Linting Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Reactive Oxygen Species, TRPC6 Cation Channel, Carrier Proteins. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Chronic kidney disease is a worldwide public health issue primarily characterized by glomerulosclerosis and the renal tubulointerstitial fibrosis. Recent studies have shown that TRPC6 is essential in renal interstitial fibrosis, although the precise mechanisms involved are not yet fully understood.
Methods
UUO model was established using C57BL/6 male mice in which HK-2 cells were stimulated with TGF-β1. H&E and Masson staining were used to observe pathological changes. IHC staining was also conducted to measure the α-SMA, fibronectin (Fn), TRPC6, reactive oxygen species (ROS), and NLRP3 expressions. Scanning electron microscopy was used to observe morphological changes in the tubular cell membrane, and flow cytometry was utilized to measure ROS levels. In addition, Western blotting was performed to detect Fn, α-SMA, TRPC6, TXNIP, NLRP3, and the downstream pyroptosis-related molecule levels.
Results
TRPC6 protein levels were enhanced in UUO mice and HK-2 cells upon TGF-β1 stimulation, which coincided with noticeable morphological changes associated with pyroptosis. Treatment with the TRPC6 inhibitor SAR7334 effectively reduced renal fibrosis markers and diminished levels of ROS, TXNIP, and proteins related to NLRP3-mediated pyroptosis (including NLRP3, cGSDMD, and IL-1β). Furthermore, application of the NLRP3 inhibitor MCC950 in HK-2 cells reinforced our findings, as it attenuated renal fibrosis-related proteins and counteracted the elevated levels of Fn, α-SMA, and NLRP3-mediated pyroptosis proteins observed in TGF-β1-stimulated HK-2 cells. Additionally, inhibiting TRPC6 appeared to dampen the activity of the ROS/TXNIP/NLRP3 pathway.
Conclusion
TRPC6 may represent a promising target for mitigating renal interstitial fibrosis, potentially through its effects on the ROS/TXNIP regulatory pathway involving NLRP3-mediated pyroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of General Surgery, The First Affiliated Hospital of Xi'an Medical University, Xi'an, China.
- Department of Nephrology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, fu_rongguo@sina.com.
Zitieren
APA
Wei, L., Cui, C., Li, Y., Ge, P., Li, K., Wang, H., Zhao, W., Wang, Y., Zhang, J., & Fu, R. (2026). TRPC6 Inhibition Attenuates Renal Tubulointerstitial Fibrosis via the Reactive Oxygen Species/TXNIP/NLRP3 Signaling Pathway. Kidney and Blood Pressure Research, 51(1), 452-467. https://doi.org/10.1159/000552129
Vancouver
Wei L, Cui C, Li Y, Ge P, Li K, Wang H, et al. TRPC6 Inhibition Attenuates Renal Tubulointerstitial Fibrosis via the Reactive Oxygen Species/TXNIP/NLRP3 Signaling Pathway. Kidney and Blood Pressure Research. 2026;51(1):452-467. doi:10.1159/000552129
BibTeX
@article{Wei2026,
author = {Wei, Linting and Cui, Chenkai and Li, Yan and Ge, Pengbo and Li, Ke and Wang, Haodong and Zhao, Weihao and Wang, Yinhong and Zhang, Jianpeng and Fu, Rongguo},
title = {TRPC6 Inhibition Attenuates Renal Tubulointerstitial Fibrosis via the Reactive Oxygen Species/TXNIP/NLRP3 Signaling Pathway},
journal = {Kidney and Blood Pressure Research},
year = {2026},
volume = {51},
number = {1},
pages = {452--467},
doi = {10.1159/000552129}
}
EUVIMED